BRETON (01333) subsidiary enters into a contract for the purchase of energy storage system equipment.
Boruiton (01333) announces that on February 10, 2026, the company's indirect non-wholly-owned subsidiary AFRICA POWER PLATFORM II LIMITED (Africa Power Platform Company, as the purchaser) entered into an energy storage system equipment procurement contract with an independent third party GREEN POWER TECHNOLOGIE (Green Power Technology Company, as the supplier). The contract pertains to the equipment procurement, supply, and related services for the Vawasi Microgrid Project in the Republic of Congo (DRC).
BRETON (01333) announces that on February 10, 2026, its indirectly non-wholly owned subsidiary, AFRICA POWER PLATFORM II LIMITED (Africa Power Platform Company, as the purchaser), entered into an energy storage system equipment purchase contract with an independent third party, GREEN POWER TECHNOLOGIE (Green Power Technology Company, as the supplier), regarding the equipment purchase, supply, and related services for the Vasimicrogrid project in the Democratic Republic of Congo. On the same day, the company (as the guarantor) issued an irrevocable joint liability guarantee letter to the supplier for the purchaser's payment obligations under the purchase contract. The purchased products mainly include energy storage battery cabinets, PCS and brackets, photovoltaic inverters, auxiliary transformers, intelligent power station management systems, microgrid controllers and related software, as well as necessary accessories and spare parts.
Related Articles

Consumer demand driven, HUITONGDA NET (09878) hard discount supermarket "accelerates upgrade"

WUXI BIO (02269) YINGXI: Shareholders' net profit in 2025 increased by 46.3% year-on-year.

ABBISKO-B(02256): The FGFR4 inhibitor erdafitinib has completed the global phase I study extension stage with the first patient dosed in the United States.
Consumer demand driven, HUITONGDA NET (09878) hard discount supermarket "accelerates upgrade"

WUXI BIO (02269) YINGXI: Shareholders' net profit in 2025 increased by 46.3% year-on-year.

ABBISKO-B(02256): The FGFR4 inhibitor erdafitinib has completed the global phase I study extension stage with the first patient dosed in the United States.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


